These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9597517)

  • 1. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition.
    Ferguson JJ; Waly HM; Wilson JM
    Eur Heart J; 1998 Apr; 19 Suppl D():D3-9. PubMed ID: 9597517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition.
    Ferguson JJ; Waly HM; Wilson JM
    Am Heart J; 1998 Apr; 135(4):S35-42. PubMed ID: 9539494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography.
    Mousa SA
    Blood Coagul Fibrinolysis; 2007 Jan; 18(1):55-60. PubMed ID: 17179828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
    Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M
    Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycoprotein IIb/IIIa antagonists: do they have a role in the management of unstable angina?
    Redwood S; Marber M; Jackson G
    Int J Clin Pract; 1999 Dec; 53(8):618-22. PubMed ID: 10692757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New aspects of blood coagulation inhibitory therapy within the scope of percutaneous transluminal coronary angioplasty (PTCA)].
    Schächinger V; Zeiher AM
    Z Kardiol; 1995 Sep; 84(9):651-67. PubMed ID: 8525667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization procedures.
    Dangas G; Fuster V
    Rev Port Cardiol; 1999 Feb; 18 Suppl 1():I49-53. PubMed ID: 10191675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The scientific basis for combined platelet and thrombin-directed pharmacotherapy in acute coronary syndromes.
    Becker RC
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E19-24;discussion E25-8. PubMed ID: 11156725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
    Ferguson JJ; Wilson JM; Diez J
    Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective use of platelet glycoprotein IIb/IIIa receptor blockers in the emergency department setting.
    Gibler WB; Wilcox RG; Bode C; Castaigne AD; Delooz H; Elich D; Fox KA; Kereiakes DJ; Rupprecht H; Topol EJ
    Eur J Emerg Med; 1998 Dec; 5(4):391-402. PubMed ID: 9919443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic drugs in vascular medicine: a historical perspective.
    Schrör K
    Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical studies on glycoprotein IIb/IIIa receptor antagonist].
    Rasmussen LH; Husted SE; Clemmensen PM; Gøtzsche CO; Helqvist S; Kristensen SD; Pedersen KE; Rasmussen K; Rasmussen S
    Ugeskr Laeger; 2000 Oct; 162(44):5944-7. PubMed ID: 11094564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons.
    Rao AK; Sun L; Hiramatsu Y; Gorman JH; Edmunds LH
    Thromb Haemost; 1999 Jul; 82(1):140-4. PubMed ID: 10456468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of platelet contractile force as a research and clinical measure of platelet function.
    Carr ME
    Cell Biochem Biophys; 2003; 38(1):55-78. PubMed ID: 12663942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia.
    Mousa SA; Ahmad S
    Am J Hematol; 2007 Apr; 82(4):276-82. PubMed ID: 17039513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
    Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet activation and progression to complications.
    Kereiakes DJ; Michelson AD
    Rev Cardiovasc Med; 2006; 7(2):75-81. PubMed ID: 16915126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.